Seeking Alpha
 

Alnylam Pharmaceuticals, Inc. (ALNY)

- NASDAQ
  • Mar. 6, 2014, 9:22 AM
    | 3 Comments
  • Jan. 13, 2014, 3:29 AM
    • Sanofi (SNY) has agreed to acquire a 12% holding in Alnylam Pharmaceuticals (ALNY) for $700M in a deal that will also deepen the companies' co-operation in the development of therapies for rare genetic diseases.
    • Sanofi is paying $80 a share for the stake, a 21% premium to Alnylam's closing price of $66.21 on Friday.
    • Sanofi and Alnylam will expand their partnership involving Patisiran, a development-stage treatment for a rare life-threatening nervous-system disease called transthyretin-familial amyloid polyneuropathy. Sanofi will sell Patisiran in all markets outside North America and Western Europe, adding to its rights in Japan and Asia-Pacific.
    • Sanofi will gain the rights to develop and market three other drugs as well, and an option on all of Alnylam's drugs for rare genetic diseases.
    • The deal comes after Sanofi suffered a patent cliff in which it lost IP protection on nine drugs in three years. (PR)
    | Comment!
ALNY vs. ETF Alternatives
Company Description
Alnylam Pharmaceuticals Inc is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
Sector: Healthcare
Industry: Biotechnology
Country: United States